PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展

doi:10.3760/cma.j.cn371439-20200610-00022

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (2): 113-116.doi: 10.3760/cma.j.cn371439-20200610-00022

PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展

丁艳, 汪红艳()

安徽医科大学第一附属医院肿瘤放疗科,合肥 230000

收稿日期:2020-06-10 修回日期:2020-06-21 出版日期:2021-02-08 发布日期:2021-03-11
通讯作者: 汪红艳 E-mail:whhy5000@163.com
基金资助:
安徽省高校自然科学研究项目(KJ2016A341);安徽省教学研究项目(2019jyxm0994)

Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma

Ding Yan, Wang Hongyan()

Department of Radiation Oncology, First Affiliated Hospital of Anhui Medical University, Hefei 230000, China

Received:2020-06-10 Revised:2020-06-21 Online:2021-02-08 Published:2021-03-11
Contact: Wang Hongyan E-mail:whhy5000@163.com
Supported by:
Natural Science Research Project of Colleges and Universities of Anhui Province of China(KJ2016A341);Teaching Research Project of Anhui Province of China(2019jyxm0994)

摘要/Abstract

摘要：

在亚洲食管癌确诊病例中,食管鳞状细胞癌(ESCC)占90%以上,且恶性程度高。目前针对ESCC免疫治疗的研究越来越多,尤其是关于程序性死亡蛋白-1(PD-1)和程序性死亡蛋白-配体1(PD-L1)的研究。在ESCC中研究最多的PD-1/PD-L1抑制剂主要有纳武单抗、帕博利珠单抗、卡瑞利珠单抗、特瑞普利单抗、替雷利珠单抗、阿特珠单抗、SHR-1316和度伐利尤单抗,这些药物的临床试验部分已经初步显示出良好的疗效,部分研究还在进行中。

关键词: 食管肿瘤, 肿瘤,鳞状细胞, PD-1, PD-L1

Abstract:

Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of the confirmed cases of esophageal cancer in Asia, and the degree of malignancy is high. There is a growing number of research on ESCC immunotherapy, particularly programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1). Among them, the most studied PD-1/PD-L1 inhibitors in ESCC are nivolumab, pembrolizumab, camrelizumab, toripalimab, tislelizumab, atozolizumab, SHR-1316 and durvalumab. Some of the clinical trials of these drugs are still in progress, and some have initially shown good results.

Key words: Esophageal neoplasms, Neoplasms, squamous cell, PD-1, PD-L1

丁艳, 汪红艳. PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2021, 48(2): 113-116.

Ding Yan, Wang Hongyan. Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(2): 113-116.

参考文献 24

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492 pmid: 30207593
[2]	Zeng H, Zheng R, Zhang S, et al. Esophageal cancer statistics in China, 2011: estimates based on 177 cancer registries[J]. Thoracic Cancer, 2016,7(2):232-237. DOI: 10.1111/1759-7714.12322. doi: 10.1111/1759-7714.12322 pmid: 27042227
[3]	Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015,348(6230):56-61. DOI: 10.1126/science.aaa8172. pmid: 25838373
[4]	Mimura K, Yamada L, Ujiie D, et al. Immunotherapy for esophageal squamous cell carcinoma: a review[J]. Fukushima J Med Sci, 2018,64(2):46-53. DOI: 10.5387/fms.2018-09. pmid: 30058598
[5]	Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2017,18(5):631-639. DOI: 10.1016/S1470-2045(17)30181-X. doi: 10.1016/S1470-2045(17)30181-X pmid: 28314688
[6]	Kato K, Doki Y, Ura T, et al. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer[J]. Cancer Sci, 2020,111(5):1676-1684. DOI: 10.1111/cas.14380. pmid: 32160365
[7]	Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemothe-rapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019,20(11):1506-1517. DOI: 10.1016/S1470-2045(19)30626-6. doi: 10.1016/S1470-2045(19)30626-6 pmid: 31582355
[8]	Yamamoto S, Kato K, Daiko H, et al. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: frontier (JCOG1804E)[J]. Future Oncol, 2020,16(19):1351-1357. DOI: 10.2217/fon-2020-0189. doi: 10.2217/fon-2020-0189 pmid: 32396014
[9]	Meindl-Beinker NM, Betge J, Gutting T, et al. A multicenter open-label phaseⅡ trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)[J]. BMC Cancer, 2019,19(1):231. DOI: 10.1186/s12885-019-5446-2. doi: 10.1186/s12885-019-5446-2 pmid: 30871493
[10]	Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018,36(1):61-67. DOI: 10.1200/JCO.2017.74.9846. doi: 10.1200/JCO.2017.74.9846 pmid: 29116900
[11]	Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J]. JAMA Oncol, 2019,5(4):546-550. DOI: 10.1001/jamaoncol.2018.5441. doi: 10.1001/jamaoncol.2018.5441 pmid: 30570649
[12]	Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase Ⅲ KEYNOTE-181 study[J]. J Clin Oncol, 2019,37(4_suppl):2. DOI: 10.1200/JCO.2019.37.4_suppl.2.
[13]	Barsouk A, Rawla P, Hadjinicolaou AV, et al. Targeted therapies and immunotherapies in the treatment of esophageal cancers[J]. Med Sci (Basel), 2019,7(10):100. DOI: 10.3390/medsci7100100.
[14]	Kato K, Shah MA, Enzinger P, et al. KEYNOTE-590: Phase Ⅲ study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer[J]. Future Oncol, 2019,15(10):1057-1066. DOI: 10.2217/fon-2018-0609. doi: 10.2217/fon-2018-0609 pmid: 30735435
[15]	Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020,21(6):832-842. DOI: 10.1016/S1470-2045(20)30110-8. doi: 10.1016/S1470-2045(20)30110-8 pmid: 32416073
[16]	Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study[J]. Br J Cancer, 2018,119(5):538-545. DOI: 10.1038/s41416-018-0100-3. doi: 10.1038/s41416-018-0100-3 pmid: 29755117
[17]	Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018,24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. doi: 10.1158/1078-0432.CCR-17-2439 pmid: 29358502
[18]	Finlay WJJ, Coleman JE, Edwards JS, et al. Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement[J]. MAbs, 2019,11(1):26-44. DOI: 10.1080/19420862.2018.1550321. doi: 10.1080/19420862.2018.1550321 pmid: 30541416
[19]	Zhang B, Wang X, Li Q, et al. Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma[J]. Chin J Cancer Res, 2019,31(6):910-917. DOI: 10.21147/j.issn.1000-9604.2019.06.07. doi: 10.21147/j.issn.1000-9604.2019.06.07 pmid: 31949393
[20]	Wang X, Zhang B, Chen X, et al. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esopha-geal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody[J]. Thorac Cancer, 2019,10(6):1395-1401. DOI: 10.1111/1759-7714.13083. pmid: 31017739
[21]	Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ⅰb/Ⅱ clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9):1479-1486. DOI: 10.1093/annonc/mdz197. doi: 10.1093/annonc/mdz197 pmid: 31236579
[22]	Xu J, Bai Y, Xu N, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma[J]. Clin Cancer Res, 2020,26(17):4542-4550. DOI: 10.1158/1078-0432.CCR-19-3561. doi: 10.1158/1078-0432.CCR-19-3561 pmid: 32561664
[23]	Bando H, Kotani D, Tsushima T, et al. TENERGY: multicenter phase Ⅱ study of Atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma[J]. BMC Cancer, 2020,20(1):336. DOI: 10.1186/s12885-020-06716-5. pmid: 32312286
[24]	Guimbaud R, Quéro L, Vendrely V, et al. Prodige67_ucgi33 arion: association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: a comparative randomized phase Ⅱ trial[J]. Ann Oncol, 2019,30(suppl_5):v322. DOI: 10.1093/annonc/mdz247.163.

PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展

Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[3]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[4]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[5]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[6]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[7]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[8]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[9]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟. 基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[10]	戴李宸, 胡莉钧, 于静萍. 尼妥珠单抗治疗食管鳞状细胞癌的应用进展[J]. 国际肿瘤学杂志, 2022, 49(8): 484-489.
[11]	夏玲玲, 陈永顺, 李彬, 宁婷婷, 张蔡羽天. pN₊食管鳞状细胞癌患者R0切除术后放化疗与化疗的安全性及有效性比较[J]. 国际肿瘤学杂志, 2022, 49(6): 334-339.
[12]	王悦, 呼群, 侯英伟. 表观遗传修饰对肿瘤PD-L1表达调控的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 345-348.
[13]	宁婷婷, 胡钦勇. 二甲双胍在肿瘤免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(5): 292-295.
[14]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 肌肉减少症对老年食管癌患者根治性放疗临床疗效及预后的影响[J]. 国际肿瘤学杂志, 2022, 49(4): 199-205.
[15]	丁心静, 丁江华. 皮肤免疫相关不良事件与PD-1/PD-L1抑制剂临床疗效相关性的研究进展[J]. 国际肿瘤学杂志, 2022, 49(4): 225-228.